"Science Stoppers" and the Question of Autism
Mia's Documentary Sheds Light on Autism

Fluzone High-Dose Vaccine For Elderly: Is Your Grandma Being Paid to Test It?

Grandparents It's not called a clinical trial per se - there's no placebo after all. But the elderly are now testing the new high dose Fluzone vaccines - do they know that? Are they being paid as test subjects? The vaccine has the benefit of "post licensure" testing - which means Sanofi gets to inject it into your Nana and Pop Pop before they know if A) it protects any better than regular flu shot and B) It has worse side effects. Bolding within doc is ours. Read original doc HERE.

Licensure of a High-Dose Inactivated Influenza Vaccine for Persons Aged ≥65 Years (Fluzone High-Dose) and Guidance for Use --- United States, 2010
Weekly April 30, 2010 / 59(16);485-486


Persons aged ≥65 years are at greater risk for hospitalization and death from seasonal influenza compared with other age groups (1,2), and they respond to vaccination with lower antibody titers to influenza hemagglutinin (an established correlate of protection against influenza) compared with younger adults (3). On December 23, 2009, the Food and Drug Administration (FDA) licensed an injectable inactivated trivalent influenza vaccine (Fluzone High-Dose, Sanofi-Pasteur) that contains an increased amount of influenza virus hemagglutinin antigen compared with other inactivated influenza vaccines such as Fluzone. Fluzone High-Dose is licensed as a single dose for use among persons aged ≥65 years and will be available beginning with the 2010--11 influenza season. The Advisory Committee on Immunization Practices (ACIP) reviewed data from prelicensure clinical trials on the safety and immunogenicity of Fluzone High-Dose and expressed no preference for the new vaccine over other inactivated trivalent influenza vaccines (4). This report summarizes the FDA-approved indications for Fluzone High-Dose and provides guidance from ACIP for its use.

Standard dose inactivated trivalent influenza vaccines contain a total of 45 µg (15 µg of each of the three recommended strains) of influenza virus hemagglutinin antigen per 0.5mL dose (5). In contrast, Fluzone High-Dose is formulated to contain a total of 180 µg (60 µg of each strain) of influenza virus hemagglutinin antigen in each 0.5mL dose. Like other inactivated influenza vaccines, Fluzone High-Dose is administered as an intramuscular injection (6). Fluzone High-Dose is available as a single-dose prefilled syringe formulation and is distinguished from Fluzone by a gray syringe plunger rod. As with other 2010--11 influenza vaccines, Fluzone High-Dose will contain antigens of the three recommended virus strains: A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like (7).

Immunogenicity data from three studies among persons aged ≥65 years indicated that, compared with standard dose Fluzone, preparations of Fluzone High-Dose elicited significantly higher hemagglutination inhibition (HI) titers against all three influenza virus strains that were included in seasonal influenza vaccines recommended during the study period (8--10). In one study, prespecified criteria for superiority, defined as when the lower 95% confidence limit of 1) a ratio of geometric mean HI titers is >1.5 for at least two strains and 2) the difference in fourfold rise of HI titers is >10% for at least two strains, were demonstrated for persons aged ≥65 years who received Fluzone High-Dose compared with Fluzone for influenza A(H1N1) and influenza A(H3N2) antigens. Prespecified criteria for noninferiority to Fluzone were demonstrated for the influenza B antigen (6,9). Whether the higher postvaccination immune responses observed among Fluzone High-Dose vaccine recipients will result in greater protection against influenza illness is unknown.

Solicited injection site reactions and systemic adverse events were more frequent after vaccination with Fluzone High-Dose compared with standard Fluzone, but typically were mild and transient (8--10). In the largest study, 915 (36%) of 2,572 persons who received Fluzone High-Dose, compared with 306 (24%) of 1,275 persons who received Fluzone, reported injection site pain ≤7 days after vaccine administration. In the same study, significantly more Fluzone High-Dose recipients (1.1%) reported moderate (>100.4°F--≤102.2°F [>38°C--≤39°C]) to severe (>102.2°F [>39°C]) fever, compared with Fluzone recipients (0.3%)(9).

ACIP Guidance for Use of Fluzone High-Dose

Fluzone High-Dose may be used for persons aged ≥65 years. All persons aged ≥6 months are recommended for annual influenza vaccination beginning with the 2010--11 influenza season. ACIP has not expressed a preference for any specific licensed inactivated trivalent influenza vaccine, including Fluzone High-Dose, for use in persons aged ≥65 years (4). Data demonstrating greater protection against influenza illness after vaccination with Fluzone High-Dose are needed to evaluate whether Fluzone High-Dose is a more effective vaccine for persons aged ≥65 years. A 3-year postlicensure study of the vaccine effectiveness of Fluzone High-Dose compared with standard dose inactivated influenza vaccine (Fluzone) was begun in 2009 and should be completed in 2012. As with other inactivated influenza vaccines, Fluzone High-Dose should not be administered to anyone with a known hypersensitivity to egg proteins or influenza vaccine. Adverse events after receipt of any vaccine should be reported to the Vaccine Adverse Event Reporting System at http://vaers.hhs.gov.

References
1.Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333--40.
2.Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179--86.
3.Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006;24:1159--69.
4.CDC. ACIP provisional recommendations for the use of influenza vaccines. Atlanta, GA, US Department of Health and Human Services, CDC; 2010. Available at http://www.cdc.gov/vaccines/recs/provisional/downloads/flu-vac-mar-2010-508.pdf . Accessed April 23, 2010.
5.CDC. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR 2009;58(No. RR-8).
6.Sanofi Pasteur, Inc. Fluzone and Fluzone High-Dose [prescribing information]. Swiftwater, PA: Sanofi Pasteur, Inc.; 2009. Available at http://www.fda.gov/downloads/biologicsbloodvaccines/.../ucm195479.pdf . Accessed April 23, 2010.
7.Food and Drug Administration. Influenza virus vaccine for the 2010--2011 season. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2010. Available at http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/post-marketactivities/lotreleases/ucm202750.htm. Accessed April 23, 2010.
8.Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007;25:7656--63.
9.Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009;200:172--80.
10.Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006;166:1121--7.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
 

All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

 This is some really long text to take up some space for Firefox and force the page to take up 100% of the available screen width. This style should not be deleted.File Formats Help:







How do I view different file formats (PDF, DOC, PPT, MPEG) on this site?
EmailPrintShare
 
Add this to...
FavoritesDel.icio.usDiggFacebookGoogle BookmarksYahoo MyWeb

DownloadUpdatesSubscribeListenSearchPage last reviewed: April 30, 2010
Page last updated: April 30, 2010
Content source: Centers for Disease Control and Prevention
HomeA-Z IndexSite MapPoliciesAbout CDC.govLink to UsAll LanguagesCDC MobileContact CDCCenters for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348, 24 Hours/Every Day - cdcinfo@cdc.gov
MMWR 
All CDC Topics
Search The CDC Choose a topic above
Search Button    A-Z IndexABCDEFGHIJKLMNOPQRSTUVWXYZ#

Comments

Benedetta

Unfortunally;
My 86 year old father would be the first in line, telling me as he walks to the car to get in to go get it - about a quarter of and inch an hour that he has no problems with vaccines.

Theodora Trudorn

If they take it mandatory they are going to have you know what to pay!!!

You come after my Granny pharma and I'll declare world war 3!! Trust me, you don't want to go there!!

I have more than enough damage for the entire family throughout my body!!

patrons99

Social Darwinism has replaced “survival of the fittest”.

“It's the new "civic responsibility" to gracefully accept your poison and then lay down and die.” -- Nicole M. (from another AoA thread)

Just "part of the normal aging process"? Sure it is! "lab rats"? No kidding!!!

Pharma is simply culling-the-herd of “useless feeders” employing the biggest portal of diseases in the world today, the vaccine schedules. It’s a false-flag campaign against the people.

http://seeker401.wordpress.com/2009/09/24/merck-admits-putting-cancer-viruses-in-vaccines/

http://www.antifascistencyclopedia.com/allposts/the-progeny-of-ig-farben-corruption-in-the-pharmaceutical-industry-is-a-minimal-risk-enterprise

“Vaccine Deaths And Injuries Skyrocket As Cover-Up Implodes” by Paul Joseph Watson on August 30, 2010.

http://www.prisonplanet.com/vaccine-deaths-and-injuries-skyrocket-as-cover-up-implodes.html

Theresa O

...and of course any side effects can be explained away as part of the "normal" aging process. Grr.

rileysmom

Well, hell. Why should they be? No one asked me for MY permission or asked ME how much money my son's brain was worth to him or me when Dr Khalid Iqbal was doing an uninformed consent study on my son out of his office.
Everyone does realize I'm being sarcastic right? We and our children were all lab rats at one time or another and didn't even know it. Just look at the Gardasil Girls, talk about an experiment gone wrong, huh?

Verify your Comment

Previewing your Comment

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

Comments are moderated, and will not appear until the author has approved them.

Your Information

(Name and email address are required. Email address will not be displayed with the comment.)